Celon Pharma

Celon Pharma EBITDA per Share

The EBITDA per Share of Celon Pharma (CLN.WA) as of Nov 4, 2026 is -1.05 PLN. In the previous year, EBITDA per Share was 0.31 PLN — a change of -441.72% (lower).

EBITDA per Share

-1.05PLN

YoY

-441.72%

Last updated:

EBITDA per Share of Celon Pharma is 2025 -1.05 PLN. EBITDA per Share of Celon Pharma was 2024 0.31 PLN. It decreases by -441.72% lower compared to the previous year.

The Celon Pharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
1.17 PLN
Jan 1, 2019
0.61 PLN
Jan 1, 2020
0.67 PLN
Jan 1, 2021
0.68 PLN
Jan 1, 2022
-0.50 PLN
Jan 1, 2023
0.44 PLN
Jan 1, 2024
0.31 PLN
Jan 1, 2025
-1.05 PLN
The Celon Pharma EBITDA per Share history
YEAREBITDA per ShareYoY
-1.05PLN-441.72%
0.31PLN-30.43%
0.44PLN-188.16%
-0.50PLN-173.44%
0.68PLN+2.69%
0.67PLN+9.05%
0.61PLN-47.91%
1.17PLN+22.14%
0.96PLN-28.40%
1.34PLN-27.26%
1.85PLN+240.60%
0.54PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celon Pharma Stock analysis

What does Celon Pharma do? Celon Pharma SA develops and manufactures generic drugs for cancer, neurological diseases, diabetes, and metabolic disorders. Its product portfolio includes pills like Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder Salmex. The company operates through its research center focused on oncology, neurology, and inflammatory and metabolic diseases. As a subsidiary of Glatton sp z o o, Celon Pharma SA serves healthcare providers and patients seeking affordable treatment options for chronic conditions. Celon Pharma SA's revenue comes from selling its generic drug portfolio to pharmacies, hospitals, and healthcare institutions. The firm's products target patients with conditions such as cancer, neurological disorders, and diabetes, where cost-effective alternatives are in demand. Glatton sp z o o, the parent company, likely oversees strategic direction and resource allocation for Celon Pharma SA's operations. The company's focus on generic drugs positions it within the pharmaceutical market segment for affordable treatments. Its research center develops new formulations within therapeutic areas like oncology and neurology, supporting ongoing product innovation. Celon Pharma SA's product lineup, including inhalation powder Salmex and pill-based treatments, caters to specific medical needs across multiple disease categories. Celon Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celon Pharma stock

EBITDA per Share of Celon Pharma is -1.05 PLN in 2025.

EBITDA per Share of Celon Pharma changed from 0.31 PLN to -1.05 PLN, representing a -441.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Celon Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Celon Pharma

All Key Metrics — Celon Pharma